|
Vol 49(2015) N 1 p. 48-57; DOI 10.1134/S0026893315010161 V.V. Vlassov1, E.Yu. Rykova1*, A.A. Ponomaryova2,4, I.A. Zaporozhchenko1, E.S. Morozkin1, N.V. Cherdyntseva2,3, P.P. Laktionov1 Circulating microRNAs in lung cancer: prospects for diagnosis, prognosis, and prediction of antitumor treatment efficacy 1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia2Tomsk Cancer Research Institute, Tomsk, 634009 Russia 3National Research Tomsk State University, Tomsk, 634050 Russia 4National Research Polytechnic University, Tomsk, 634050 Russia *rykova@niboch.nsc.ru Received - 2014-07-17; Accepted - 2014-08-13 The review considers the main techniques to extract microRNA (miRNA) from various biological fluids (in particular, the serum and plasma), approaches to the analysis of miRNA concentration and composition, and methods to normalize the results in data analyses. Advantages and drawbacks of the methods are described. Special attention is given to circulating miRNAs, which can be used as markers for minimally invasive diagnosis, prediction of antitumor treatment efficacy, and disease prognosis in lung cancer. The review discusses the prospects and limitations that arise as the clinical significance is evaluated for miRNAs as potential tumor markers and a better understanding is gained for the roles various miRNAs play in the pathogenesis of lung cancer. lung cancer, diagnosis, prognosis, tumor markers, circulating microRNAs |